Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CLSTN1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CLSTN1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CLSTN1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CLSTN1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CLSTN1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CLSTN1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CLSTN1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CLSTN1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CLSTN1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19907784 | Colorectum | FAP | protein localization to cell periphery | 100/2622 | 333/18723 | 2.19e-14 | 2.68e-11 | 100 |
GO:00343293 | Colorectum | FAP | cell junction assembly | 105/2622 | 420/18723 | 1.03e-09 | 2.18e-07 | 105 |
GO:00160493 | Colorectum | FAP | cell growth | 112/2622 | 482/18723 | 2.40e-08 | 2.30e-06 | 112 |
GO:00901504 | Colorectum | FAP | establishment of protein localization to membrane | 69/2622 | 260/18723 | 6.40e-08 | 4.54e-06 | 69 |
GO:00988763 | Colorectum | FAP | vesicle-mediated transport to the plasma membrane | 42/2622 | 136/18723 | 3.16e-07 | 1.78e-05 | 42 |
GO:00015583 | Colorectum | FAP | regulation of cell growth | 95/2622 | 414/18723 | 5.02e-07 | 2.61e-05 | 95 |
GO:00990032 | Colorectum | FAP | vesicle-mediated transport in synapse | 51/2622 | 200/18723 | 1.09e-05 | 3.08e-04 | 51 |
GO:00508083 | Colorectum | FAP | synapse organization | 91/2622 | 426/18723 | 1.90e-05 | 4.74e-04 | 91 |
GO:00519601 | Colorectum | FAP | regulation of nervous system development | 89/2622 | 443/18723 | 2.32e-04 | 3.25e-03 | 89 |
GO:19018882 | Colorectum | FAP | regulation of cell junction assembly | 47/2622 | 204/18723 | 3.25e-04 | 4.16e-03 | 47 |
GO:00508071 | Colorectum | FAP | regulation of synapse organization | 46/2622 | 211/18723 | 1.30e-03 | 1.20e-02 | 46 |
GO:00990722 | Colorectum | FAP | regulation of postsynaptic membrane neurotransmitter receptor levels | 18/2622 | 62/18723 | 1.60e-03 | 1.42e-02 | 18 |
GO:0051962 | Colorectum | FAP | positive regulation of nervous system development | 56/2622 | 272/18723 | 1.74e-03 | 1.52e-02 | 56 |
GO:0021700 | Colorectum | FAP | developmental maturation | 57/2622 | 280/18723 | 2.08e-03 | 1.72e-02 | 57 |
GO:0050803 | Colorectum | FAP | regulation of synapse structure or activity | 46/2622 | 218/18723 | 2.59e-03 | 2.03e-02 | 46 |
GO:19024141 | Colorectum | FAP | protein localization to cell junction | 23/2622 | 94/18723 | 4.64e-03 | 3.14e-02 | 23 |
GO:19907785 | Colorectum | CRC | protein localization to cell periphery | 85/2078 | 333/18723 | 8.75e-14 | 1.05e-10 | 85 |
GO:00160494 | Colorectum | CRC | cell growth | 95/2078 | 482/18723 | 1.51e-08 | 2.75e-06 | 95 |
GO:00343294 | Colorectum | CRC | cell junction assembly | 83/2078 | 420/18723 | 1.08e-07 | 1.29e-05 | 83 |
GO:00988764 | Colorectum | CRC | vesicle-mediated transport to the plasma membrane | 36/2078 | 136/18723 | 4.65e-07 | 3.40e-05 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLSTN1 | SNV | Missense_Mutation | rs751480577 | c.1498N>A | p.Val500Met | p.V500M | O94985 | protein_coding | tolerated(0.35) | probably_damaging(0.942) | TCGA-A2-A3XV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
CLSTN1 | SNV | Missense_Mutation | rs201194236 | c.2146N>A | p.Asp716Asn | p.D716N | O94985 | protein_coding | tolerated(1) | benign(0.003) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
CLSTN1 | SNV | Missense_Mutation | rs749257979 | c.2896N>A | p.Ala966Thr | p.A966T | O94985 | protein_coding | tolerated(0.32) | benign(0.001) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
CLSTN1 | SNV | Missense_Mutation | | c.1270N>T | p.Gly424Trp | p.G424W | O94985 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-EW-A6S9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CLSTN1 | insertion | Frame_Shift_Ins | novel | c.1656dupG | p.Lys553GlufsTer48 | p.K553Efs*48 | O94985 | protein_coding | | | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
CLSTN1 | insertion | In_Frame_Ins | novel | c.1654_1655insCGCCAGTGCTTCCCAAACGACCCATGGGGA | p.Asp551_Lys552insThrProValLeuProLysArgProMetGly | p.D551_K552insTPVLPKRPMG | O94985 | protein_coding | | | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
CLSTN1 | insertion | Frame_Shift_Ins | novel | c.774_775insG | p.Pro259AlafsTer15 | p.P259Afs*15 | O94985 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
CLSTN1 | insertion | Frame_Shift_Ins | novel | c.772_773insGACAGAGTCTCACTCTGTCACCC | p.Lys258ArgfsTer56 | p.K258Rfs*56 | O94985 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
CLSTN1 | deletion | Frame_Shift_Del | novel | c.755delT | p.Leu252TrpfsTer2 | p.L252Wfs*2 | O94985 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CLSTN1 | SNV | Missense_Mutation | rs778535987 | c.709G>A | p.Val237Ile | p.V237I | O94985 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |